Transarterial chemoembolization and bland embolization for hepatocellular carcinoma

Area of Science:

• Interventional Radiology
• Hepatobiliary Oncology
• Medical Oncology

Background:

• Transarterial chemoembolization (TACE) is a primary treatment for intermediate-stage hepatocellular carcinoma (HCC).
• TACE is also utilized in liver transplant candidates to control tumor progression.
• Significant procedural variability exists in TACE regarding embolic agents, chemotherapy, and treatment intervals.

Purpose of the Study:

• To review the current applications of TACE and TAE in hepatocellular carcinoma management.
• To critically evaluate the existing evidence supporting the use of TACE and TAE for HCC.

Main Methods:

• Review of existing randomized controlled trials and clinical evidence.
• Analysis of procedural variations in TACE and TAE.

Main Results:

• Randomized controlled trials indicate that bland transarterial embolization (TAE) demonstrates comparable efficacy to TACE.
• The unstandardized nature of TACE presents challenges in treatment consistency and outcome interpretation.

Conclusions:

• Both TACE and TAE are relevant treatment options for hepatocellular carcinoma.
• Further standardization of TACE procedures is warranted to optimize patient outcomes and treatment efficacy.